Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: c-Met–dependent tumors in animal models
Authors:
- 1 May 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 8 (5) , 1119-1125
Abstract
C-Met is a receptor tyrosine kinase frequently overexpressed or amplified in many types of human cancers. Hepatocyte growth factor (HGF, also known as scatter factor) is the only known ligand for c-Met. In this study, soluble human and murine c-Met receptor-Fc fusion proteins were generated and were shown to bind to human and murine HGF as measured by fluorescence-activated cell sorting and surface plasmon resonance (Biacore) assays. Also, both human and murine c-Met-Fc showed activity in functional cell assays, inhibiting HGF-induced c-Met phosphorylation in PC3 and 4T1 cells, respectively, and inhibiting HGF-driven cellular invasion in a dose-dependent manner. Pharmacokinetic analysis showed that both reagents were suitable for in vivo testing. Systemic administration of human c-Met-Fc significantly inhibited tumor growth in the human HGF-dependent U-87 MG xenograft model at daily doses of 30 or 100 μg (P < 0.0001). Similarly, murine c-Met-Fc, at 100 μg daily, significantly inhibited tumor growth in the murine HGF–dependent CT-26 syngeneic tumor model (P < 0.002). Human and murine c-Met-Fc seemed to be well-tolerated in animals. In conclusion, both mouse and human versions of c-Met-Fc effectively block HGF-induced activation of c-Met and inhibit growth of tumor xenografts, providing further evidence that c-Met is an important target for oncology therapeutics.[Mol Cancer Ther 2009;8(5):1119–25]Keywords
This publication has 38 references indexed in Scilit:
- Drug development of MET inhibitors: targeting oncogene addiction and expedienceNature Reviews Drug Discovery, 2008
- Discovery and Optimization of Triazolopyridazines as Potent and Selective Inhibitors of the c-Met KinaseJournal of Medicinal Chemistry, 2008
- AMG 102, A Fully Human Anti-Hepatocyte Growth Factor/Scatter Factor Neutralizing Antibody, Enhances the Efficacy of Temozolomide or Docetaxel in U-87 MG Cells and XenograftsClinical Cancer Research, 2007
- A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivoClinical Cancer Research, 2006
- Expression of hepatocyte growth factor and c-Met in hypopharyngeal squamous cell carcinomaActa Oto-Laryngologica, 2006
- Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factorOncogene, 2004
- Novel Membrane Protein shrew-1 Targets to Cadherin-Mediated Junctions in Polarized Epithelial CellsMolecular Biology of the Cell, 2004
- Novel mutations of the MET proto-oncogene in papillary renal carcinomasOncogene, 1999
- The clinical significance of hepatocyte growth factor for non–small cell lung cancerThe Annals of Thoracic Surgery, 1998
- Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development.Journal of Cell Biology, 1993